CG Oncology Secures $105M to Propel Breakthrough Bladder Cancer Immunotherapy Development

CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company committed to advancing bladder-sparing treatments, is thrilled to announce the successful raising of $105 million in new funding. This significant capital infusion will accelerate the development and commercialization of their innovative oncolytic immunotherapy approach, which is poised to transform the standard of care for patients battling bladder cancer. With a clear vision of a future where urologic cancer patients live with dignity and enjoy an enhanced quality of life, CG Oncology is leveraging this funding to further advance its lead candidate, cretostimogene grenadenorepvec. Currently in a Phase 3 trial targeting BCG-unresponsive non-muscle invasive bladder cancer through intravesical delivery, this therapy represents a potential breakthrough in bladder-sparing treatment. Moreover, the company is exploring its versatility by investigating cretostimogene grenadenorepvec in combination with KEYTRUDA® (pembrolizumab) in Phase 2 trials for similar indications, as well as its application with OPDIVO® (nivolumab) in other bladder cancer contexts. The additional funds will support a broad range of activities, including expanding clinical trial programs, enhancing manufacturing capabilities, and bolstering the regulatory process necessary for global commercialization. With unwavering dedication to improving patient outcomes, CG Oncology’s strategic investment in research and development underscores the critical importance of innovative therapies in oncology. This funding milestone not only validates the company’s pioneering scientific approach but also sets the stage for potentially life-altering advancements in the treatment of bladder cancer, marking an exciting new chapter in their mission to redefine late-stage biopharmaceutical care.